Plasma Cell Tumor of the Skin or Mucosa in Dogs (Mucocutaneous Plasmacytoma)
- Occurrence: very rare
- Location of disease: Skin/Fur
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Das Wichtigste auf einen Blick
Mucocutaneous plasmacytomas in dogs arise from uncontrolled proliferation of plasma cells, which develop from B-lymphocytes and produce antibodies. These tumors often appear as raised nodules on the skin and mucous membranes. The exact causes are unclear, but genetic and environmental factors as well as possibly immunological dysregulation could play a role. Certain dog breeds and older dogs are more frequently affected. Symptoms include skin changes, nodule formation, and itching. Diagnosis requires a histopathological examination following a biopsy. Supplementary tests such as blood tests and imaging procedures help assess the extent of the disease. Treatment depends on the size and location of the tumor and usually involves surgical removal. Radiation therapy or chemotherapy may be necessary if the tumor cannot be completely removed. The prognosis is generally good, as most tumors are benign. Early detection and treatment are crucial. Preventive measures include regular veterinary examinations, a healthy diet, and protection from excessive sun exposure. Research is focusing on genetic markers, improved diagnostic methods, and new treatment approaches such as immunotherapies. Long-term studies aim to improve the quality of life of affected dogs.
Ursachen
Plasma cells are specialized white blood cells that play an important role in the immune system by producing antibodies. These cells develop from B-lymphocytes, which play a crucial role in the immune response against infections. In the development of a mucocutaneous plasmacytoma, uncontrolled proliferation of these plasma cells occurs.
These tumors often appear as raised, well-defined cutaneous nodules on the skin or mucous membranes. The exact cause of plasmacytoma development is not fully understood, but it is believed that genetic factors, environmental factors, and possibly immunological dysregulation may play a role.
Some breeds appear to have a higher predisposition for developing mucocutaneous plasmacytomas, suggesting a genetic component. Middle-aged to older dogs are more frequently affected, indicating that age-related changes in the immune system may also play a role.
Symptoms
Symptoms of a mucocutaneous plasmacytoma can vary depending on the location and size of the tumor. Typically, these tumors appear as small, raised, reddish or purple nodules on the skin or mucous membranes. They are usually well-defined and can vary in size and number.
Common locations for these tumors are the lips, gums, ears, and limbs. In some cases, they may also occur at other body sites. Most of these tumors are not painful, but may cause discomfort if irritated or infected.
Occasionally, these tumors may ulcerate or bleed, especially when located in areas subject to frequent rubbing or trauma. In rare cases, systemic symptoms such as lethargy or weight loss may occur, particularly if the tumor has reached a significant size or caused secondary complications.
Diagnose
Diagnosis of a mucocutaneous plasmacytoma typically begins with a thorough physical examination by a veterinarian. Suspicion of a plasmacytoma may be raised based on the characteristic appearance of the skin lesions.
However, a histopathological examination is required to confirm the diagnosis. This involves taking a biopsy of the tumor, which is then examined under a microscope by a pathologist. Upon histological examination, a plasmacytoma typically shows an accumulation of abnormal plasma cells.
In addition to the biopsy, the veterinarian may perform blood tests, X-rays, or ultrasound examinations to assess the extent of the disease and the presence of metastases. These additional tests are particularly important to rule out other possible causes of the symptoms and to develop a comprehensive treatment plan.
Therapie
Treatment of mucocutaneous plasmacytomas depends on several factors, including the size and location of the tumor, the dog’s age and general health, and the presence of metastases. In many cases, the primary treatment consists of surgical removal of the tumor.
Surgical procedures are usually successful, especially when the tumor is detected early and completely removed. In cases of incomplete removal or tumors in complicated locations, additional treatment may be necessary.
Radiation therapy may be considered if the tumor cannot be completely removed or if there is evidence of remaining cancerous cells. In some cases, chemotherapy may also be used, especially if the tumor is aggressive or shows signs of metastasis.
In addition to direct treatment of the tumor, supportive measures may be necessary to improve the dog’s quality of life. This may include pain management, nutritional support, and treatment of secondary infections.
Prognose und Nachsorge
The prognosis for dogs with mucocutaneous plasmacytoma is generally good, especially when the tumor is detected and treated early. Most of these tumors are benign and do not tend to metastasize, which significantly improves the chances of recovery.
With complete removal of the tumor, the likelihood of recurrence is low. However, in cases where the tumor cannot be completely removed or is more aggressive in nature, the prognosis may vary. Careful monitoring and regular follow-up examinations are important to detect recurrence or the appearance of new tumors early.
The long-term prognosis also depends on additional factors such as the dog’s general health and the presence of other diseases. Close collaboration with the veterinarian is crucial to ensure the best possible treatment and care.
Prävention
Since the exact causes of mucocutaneous plasmacytomas are not fully understood, there are no specific preventive measures for these tumors. However, there are some general recommendations that may help reduce the risk of skin cancer in dogs.
Regular examinations by a veterinarian are important to detect and treat skin changes early. Watch for unusual nodules or changes on your dog’s skin and seek veterinary advice promptly if you have concerns.
A healthy diet and a strong immune system can also help reduce the overall cancer risk. Make sure your dog receives a balanced diet and is regularly vaccinated and dewormed to maintain their health.
Protection from excessive sun exposure can also help reduce the risk of skin cancer. Avoid exposing your dog to direct sunlight during the hottest hours of the day, and use sunscreen specifically designed for pets where appropriate.
Ausblick auf aktuelle Forschung
Research on mucocutaneous plasmacytomas in dogs has made progress in recent years, particularly in the areas of molecular biology and genetic analysis. Scientists are focusing on identifying genetic markers that may be associated with the development of these tumors. By understanding the genetic basis, targeted therapies could be developed in the future that address specific genetic mutations.
Another research focus is on improving diagnostic methods. Currently, imaging techniques are being researched that could enable earlier and more accurate detection of plasmacytomas. Methods such as high-resolution ultrasound and magnetic resonance imaging (MRI) could play an important role in diagnosis in the future by providing detailed images of tumor structure.
Regarding treatment, work is underway on developing new chemotherapy drugs and immunotherapies. Immunotherapy, which stimulates the dog’s immune system to fight cancer cells itself, has shown promising results in preclinical studies. Researchers are also investigating the effectiveness of combination therapies, in which chemotherapy is combined with other forms of treatment to increase efficacy.
Long-term studies on quality of life and survival rates of dogs with mucocutaneous plasmacytoma are also ongoing. These studies aim to help better understand how different treatment approaches affect the quality of life of affected animals and how prognoses can be improved. A particular focus is on minimizing side effects and improving quality of life during and after treatment.
Finally, there are also research projects on the prevention of mucocutaneous plasmacytomas. These include investigating environmental factors that could increase the risk of developing these tumors, as well as exploring potential preventive measures that could prevent the occurrence of plasmacytomas.
Frequently Asked Questions (FAQs)
1. What is a mucocutaneous plasmacytoma in dogs?
2. How do I recognize if my dog has a mucocutaneous plasmacytoma?
3. Which dog breeds are most commonly affected?
4. How is a mucocutaneous plasmacytoma treated?
5. What is the prognosis for a dog with mucocutaneous plasmacytoma?
6. Can a mucocutaneous plasmacytoma recur?
7. What role does diet play in preventing mucocutaneous plasmacytomas?
8. Are there risk factors that promote the development of a mucocutaneous plasmacytoma?
9. Can a mucocutaneous plasmacytoma be transmitted to humans?
10. What preventive measures can I take to reduce the risk of mucocutaneous plasmacytomas?
Literatur
- Evenhuis, J. V., Oates, A., Hoyer, N., Vilander, A., Thamm, D., & Worley, D. (2023). A retrospective study of canine oral extramedullary plasmacytoma over a 15-year period (July 2004–July 2019): Treatment, histologic parameters and clinical outcomes. Veterinary and Comparative Oncology, 21(2), 302–314. https://doi.org/10.1111/vco.12888
- Cangul, I. T., Wijnen, M., Van Garderen, E., & Van Den Ingh, T. S. G. A. M. (2002). Clinico-pathological aspects of canine cutaneous and mucocutaneous plasmacytomas. Journal of Veterinary Medicine Series A, 49(6), 307–312. https://doi.org/10.1046/j.1439-0442.2002.00456.x
- Rakich, P. M., Latimer, K. S., Weiss, R., & Steffens, W. L. (1989). Mucocutaneous plasmacytomas in dogs: 75 cases (1980–1987). Journal of the American Veterinary Medical Association, 194(6), 803–810.
- Ramos-Vara, J. A., Miller, M. A., & Valli, V. E. O. (2007). Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: Comparison with CD79a and CD20. Veterinary Pathology, 44(6), 875–884. https://doi.org/10.1354/vp.44-6-875
- McHale, B., Bankhead, A., Smedley, R. C., & Kiupel, M. (2017). A divergent pseudoglandular configuration of cutaneous plasmacytomas in 6 dogs. Journal of Veterinary Diagnostic Investigation, 29(3), 344–348. https://doi.org/10.1177/1040638716689482
- Sandoval, J. C. J., Meakin, L., Cantatore, M., & Rossanese, M. (2025). Treatment, prognosis, and outcome of dogs treated for rectal plasmacytoma: A multicentric retrospective study. Journal of the American Veterinary Medical Association, 263(4), 1–8. https://doi.org/10.2460/javma.24.10.0666
- Santos, B. B. N., Peixoto, P. V., & Peleteiro, M. C. (2026). Histologic spectrum of canine extramedullary plasmacytomas: Diagnostic challenges and immunohistochemical differentiation from cutaneous histiocytomas. Veterinary Pathology, 63(1), 56–62. https://doi.org/10.1177/03009858251361141